1 / 34

Drugs for Congestive Heart Failure

Required reading: Katzung, 9 th ed . pp. 201-215, 281-290. Drugs for Congestive Heart Failure. Digitalis Lanata. Cardiovascular System Course. William B. Jeffries, Ph.D. Room 570A Criss III, 280-4092 Email: wbjeff@creighton.edu flap.creighton.edu.

tacita
Télécharger la présentation

Drugs for Congestive Heart Failure

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Required reading: Katzung, 9thed. pp. 201-215, 281-290 Drugs for Congestive Heart Failure Digitalis Lanata Cardiovascular System Course William B. Jeffries, Ph.D. Room 570A Criss III, 280-4092 Email: wbjeff@creighton.edu flap.creighton.edu

  2. Compensatory Mechanisms in Heart Failure • Mechanisms designed for acute loss in cardiac output • Chronic activation of these mechanisms worsens heart failure

  3. Potential Therapeutic Targets in Heart Failure • Preload • Afterload • Contractility • Remodeling

  4. Positive Inotropic Agents • Cardiac Glycosides • Phosphodiesterase inhibitors • b-adrenoceptor agonists

  5. Cardiac Glycosides • digoxin • digitoxin • deslanoside • ouabain

  6. Mechanism of Digitalis Action: Molecular • Inhibition of Na/K ATPase • blunting of Ca2+ extrusion • ­ Ca2+i • ­ sarcomere shortening

  7. Effects on Cardiac Function Three Types of Effects: • Mechanical Effects: Positive inotropy • Caused by increased Ca2+ Availability • Direct Electrophysiological Effects • Altered cellular action potential • Afterdepolarizations • Indirect Electrophysiological Effects: • Mediated through increased vagal tone and withdrawal of sympathetic tone

  8. Direct Electrophysiological Effects:Cellular Action Potential

  9. Afterdepolarizations

  10. Parasympathomimetic Effects • Vagus-mediated hyperpolarization of AV node. Leads to: • Decreased conduction velocity in the AV node • Increased effective refractory period in the AV node • AV block (toxic concentrations)

  11. Therapeutic Uses of Digitalis • Congestive Heart Failure • Atrial fibrillation

  12. Overall Benefit of Digitalis to Myocardial Function • ­ cardiac output • ­ cardiac efficiency • ¯ heart rate • ¯ cardiac size NO survival benefit

  13. Administration • Digoxin has a long enough half life (24-36 hr.) and high enough bioavailability to allow once daily dosing • Digoxin has a large volume of distribution and dose must be based on lean body mass • Increased cardiac performance can increase renal function and clearance of digoxin • Eubacterium lentum

  14. Adverse Effects • Cardiac • AV block • Bradycardia • Ventricular extrasystole • Arrhythmias • CNS • GI Therapeutic index is ~ 2!

  15. Serum Electrolytes Affect Toxicity • K+ • Digitalis competes for K binding at Na/K ATPase • Hypokalemia: increase toxicity • Hyperkalemia: decrease toxicity • Ca2+ • Hypercalcemia: increases toxicity

  16. Phosphodiesterase Inhibitors • amrinone • milrinone • Mechanism of Action • inhibition of type III phosphodiesterase • ­ intracellular cAMP • ­ activation of protein kinase A • Ca2+ entry through L type Ca channels • increased Ca2+ sequestration by SR • Phosphorylation of MLCK • ­ cardiac output • ¯ peripheral vascular resistance • “Inamrinone”

  17. Phosphodiesterase Inhibitors: Therapeutic Use • short term support in advanced decompensated cardiac failure • long term use not possible

  18. Adverse Effects of Phosphodiesterase Inhibitors • Cardiac arrhythmias • GI: Nausea and vomiting • Sudden death

  19. b-Adrenoceptor and Dopamine Receptor Agonists • Dobutamine • Dopamine

  20. Mechanism of Action:Dobutamine • Stimulation of cardiac b1-adrenoceptors: ­ inotropy > ­ chronotropy • peripheral vasodilatation • ­ myocardial oxygen demand

  21. Mechanism of Action: Dopamine • Stimulation of peripheral postjunctional D1 and prejunctional D2 receptors • Splanchnic and renal vasodilatation

  22. Therapeutic Use • Dobutamine:management of acute decompensated failure only • Dopamine:restore renal blood in acute failure

  23. Adverse Effects • Dobutamine • Tolerance • Tachycardia • Dopamine • Tachycardia • Arrhythmias • Peripheral vasoconstriction

  24. ACE Inhibitors in Heart Failure Therapeutic targets in heart failure

  25. Mechanism of Action • Afterload reduction • Preload reduction • Reduction of cardiac remodeling (hypertrophy) • Withdrawal of sympathetic tone

  26. ACE Inhibitors: Therapeutic Uses • Drugs of choice in heart failure (with diuretics) • Acute myocardial infarction • ATII antagonists

  27. Diuretics:Mechanism of Action in Heart Failure • Preload reduction: reduction of excess plasma volume and edema fluid • Afterload reduction: lowered blood pressure • Reduction of facilitation of sympathetic nervous system

  28. Vasodilators • Mechanism of action: reduce preload and afterload • Drugs used • Isosorbide dinitrate + Hydralazine • Demonstrated survival benefit • Inferior to ACE inhibition • Ca2+ channel blockers • No benefit in systolic failure • Use in diastolic failure? • Alpha-1 adrenergic antagonists: • no proven benefit • Neseritide

  29. Nesiritide • Recombinant B-type natriuretic peptide • Mechanism of Action • Activates smooth muscle guanylyl cyclase • Dilatation of venous and arterial beds • Natriuresis/diuresis (but not in decompensated heart failure) • Preload and afterload reduction • Reduced pulmonary capillary wedge pressure • Reduced dyspnia

  30. See: Topol, NEJM 353:2 113-116, 2005 Nesiritide • Approved in acute decompensated failure • Off Label Use: Ambulatory heart failure • Effects similar to nitrates • Adverse effects: • hypotension (NO arrhythmias) • Increased renal failure? • Increased death rate?

  31. -Blockers in Heart Failure:Mechanism of Action • Standard b-blockers: • Reduction in damaging sympathetic influences in the heart (tachycardia, arrhythmias, remodeling) • inhibition of renin release • Carvedilol: • Beta blockade effects • peripheral vasodilatation via a1-adrenoceptor blockade

  32. Aldosterone Antagonists • Rationale: • Aldosterone promotes increased plasma volume, Increased serum K, and (possibly) hypertrophic effects on the heart • Aldosterone inappropriately elevated in CHF (even after ACE inhibition) • Thus, positive outcome if aldosterone effects on heart and kidney are prevented • Evidence: Aldosterone antagonists have been shown to reduce mortality in CHF • Available aldosterone antagonists • Spironolactone • Eplerenone

  33. Spironolactone and Eplerenone • Aldosterone antagonists, K-sparing diuretics • Effects in Heart Failure • Potassium Sparing Diuretics • Mobilize edema fluid in heart failure • Prevent K loss caused by other diuretics (protection against digitalis toxicity?) • Reduction of cardiovascular remodeling • Potential side effects • Hyperkalemia • Androgenic effects (spironolactone) • Gynecomastia (spironolactone)

  34. back

More Related